pharma · Dermatitis atopic · Cancer
Sanofi-Aventis U.S
Sanofi-aventis Healthcare Pty Ltd
Sanofi-aventis Healthcare Pty is a pharma organization headquartered in Sydney, AU. Primary therapeutic focus areas include Dermatitis atopic, Cancer, Immune system diseases, Asthma, Chronic Obstructive Pulmonary Disease
Bridgewater, USA HQ
177 Employees
TGA registrant Type
Company details
- Status
- Public
- HQ
- Bridgewater, USA
- Employees
- 177
- Programs
- 117
- Drugs
- 148
- Patents
- 0
INBRX101-01-201
Phase 2 · small molecule · Alpha-1 Antitrypsin Deficiency (AATD) Emphysema
INBRX101-01-201 for Alpha-1 Antitrypsin Deficiency (AATD) Emphysema is a Phase 2 program (small_molecule) at Sanofi-aventis Healthcare Pty Ltd with 1 ClinicalTrials.gov record(s).
Internal code INBRX101-01-201
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Sanofi-aventis Healthcare Pty Ltd
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Alpha-1 Antitrypsin Deficiency (AATD) Emphysema
- Status
- active
- Trials
- 1